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OBJECTIVES: To evaluate the clinical and economic outcomes based on bariatric 
surgery type. METHODS: 2005 and 2006 National Inpatient Sample (NIS) datasets 
were utilized as the data source. The bariatric population was deﬁned by ICD-9 codes 
(44.38, 44.39, 44.68). A diagnosis of morbid obesity was required for inclusion; 
records with a diagnosis of a stomach or intestinal cancer were excluded from the 
analysis. RESULTS: Each NIS dataset contains approximately 8,000,000 hospital 
discharge records; the bariatric surgery sub-population contains 33,938 records. The 
sample population primarily consisted of females (82%) with a mean age of 43 years. 
Most of the procedures were performed at urban hospitals (53%), and the most 
common payer was private insurance (75%). Clinical and economic outcomes were 
compared by surgery type; the surgery types were: open gastric bypass (OGBP), lapa-
roscopic gastric bypass (LGBP) and laparoscopic banding procedure (LB). The most 
common procedure was the laparoscopic gastric bypass procedure (n  26,465). 
Length of stay (in days) differed signiﬁcantly between procedures (OGBP  3.8, LGBP 
 2.5, LB  1.6, p  0.0001). Total charges differed signiﬁcantly between procedures 
(OGBP  $ 40,770, LGBP  $ 37,306, LB  $ 26,859, p  0.0001). The complication 
rate was low (2% for all procedures); mortality was also low (0.5% for all proce-
dures). A multivariate model was used to assess the relationship between procedure 
type and predictor variables (age, gender, hospital location, year, and race); race, 
gender and hospital location were statistically signiﬁcant. CONCLUSIONS: The lapa-
roscopic banding procedure was associated with the least cost and shortest length of 
stay. Mortality and complication rates were low for all surgery types. Females were 
more likely to receive the laparoscopic gastric bypass; males were more likely to receive 
laparoscopic banding.
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OBJECTIVES: To compare the burden of the ankylosing spondylitis (AS) based on 
data from patient survey BEDA collected in 2005 (A) and in 2008 (B) in the Czech 
Republic. METHODS: Data of 1.008 patients (A) and 509 patients (B) with AS were 
analysed. Data on demographics, history of disease, health care consumption and 
productivity loss were analysed. For calculating of the indirect costs (work loss, 
absenteeism) the human capita approach was applied. The study was performed from 
the payer perspective (health insurance companies in the Czech Republic) and societal 
perspective (including indirect costs). The price year was 2008. Direct medical costs 
were based on the price list published by the Czech Health Insurance Companies. The 
treatment pattern was based on the guidelines of the Czech Rheumatology Society. 
RESULTS: The average time from diagnosis was 23 years (A) and 26.4 years (B); 61% 
(A) and 63% (B) were male. Around 30% (A, B) were fully disabled. Mean annual 
direct cost per patient is estimated at a1812 (45.0%) (A) and a2588 (48.2%) (B) and 
the indirect costs a2218 (55.0%) (A) and a2782 (51.8%) (B). Major contributors to 
the total direct costs were spa (45.3% (A) and 31.2% (B) of direct costs) and biological 
treatment (34.2% (A) and 52.8% (B) of direct costs). Total medication use contributed 
to 39.4% (A) and 56.3% (B) of the direct costs. CONCLUSIONS: The annual costs 
per patient with AS in the Czech Republic were a4030 and a5371 (B). Share of direct 
and indirect cost was almost equal (A, B). The distribution of costs consumption 
was similar in both groups except spa and biologic drugs treatment. Further cost-
effectiveness evaluation of the AS treatment in the Czech Republic is recommended.
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OBJECTIVES: Fibromyalgia (FM) is characterized by persistent, widespread pain and 
associated with substantial health care costs. This study examined medical resource 
use (MRU) and costs associated with FM by severity level, in Germany. METHODS: 
This cross-sectional, observational study recruited 211 FM subjects during routine 
ofﬁce visits to community-based physicians in Germany. Subjects completed questions 
about their pain, health-related quality-of-life, productivity, and out-of-pocket 
expenses related to FM; site staff recorded MRU based on medical records. FM sever-
ity was deﬁned using subjects’ FIQ total scores: 0– 39 (mild), 39– 59 (moderate), 
and 59–100 (severe). Annual costs from a societal perspective were calculated in 2008 
Euros and included direct (e.g., physician ofﬁce visits, medications, out-of-pocket, 
home health care services), and indirect (e.g., lost productivity due to absenteeism and 
disability) costs. RESULTS: The mean age (SD) of subjects was 53.7 (12.9) years, and 
79% were female. Most patients reported moderate (38%) or severe (43%) FM. 
Subjects had a mean (SD) of 4.9 (3.2) physician ofﬁce visits over the past 3 months, 
with the highest proportion of patients visiting Orthopedists (49%), Rheumatologists 
(31%), General Practitioners (15%), and Neurologists (13%). Most subjects (94%) 
were receiving at least one prescription medication for FM. The highest proportions 
of subjects were prescribed anti-inﬂammatories (67%), other analgesics (34%), and 
anti-depressants (33%). Subjects employed full- or part-time missed a mean (SD) of 
2.1 (3.8) days from work due to FM over the past 4 weeks, corresponding to 25.2 
and 32.4 work days missed annually. Total costs were a7256 (direct  a1765; indirect 
 a5491), and signiﬁcantly increased as FM severity worsened (p  0.0002). 
 CONCLUSIONS: FM imposes a substantial economic burden on society in both direct 
and indirect costs, which increases as FM severity worsens. Indirect costs due to lost 
productivity accounted for the largest proportion of total FM costs.
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OBJECTIVES: To present an overview of the burden of obesity in Ontario by using 
the richness of a Canadian population health survey linked to Ontario administrative 
databases. METHODS: The records of all Ontarians aged 12 and over who partici-
pated in the Canadian Community Health Survey (CCHS), cycle 1.1 (2000/2001) and 
provided consent to data linkage with administrative databases were linked to the 
Ontario Health Insurance Program (OHIP) claims database and the Discharge 
Abstract Database (DAD) In-Patient and Day Procedure database. Prevalence of 
obesity in this adult population was documented using the body mass index (BMI). 
Socio-demographics (e.g. age, gender, education), medical characteristics (e.g. comor-
bidities), health related quality of life (Health Utility Index 3), self-reported health and 
one-year physician and hospitalization costs were described per BMI category (e.g. 
underweight, normal weight, overweight and obese for adult and normal weight, 
overweight and obese for children). A two-part model was used to identify determi-
nants of costs. RESULTS: Twenty-three percent of children aged 12–17 were over-
weight or obese and more than 50% percent of adult participants were either 
overweight or obese in 2000/2001. Among respondents older than 18 years of age, 
differences between BMI categories were observed in terms of age, gender, marital 
status, place of birth, education, smoking status, physically activity, comorbidities and 
health-related quality of life. Costs increased signiﬁcantly with age, being male, being 
a smoker, being obese (reference: normal weight), being underweight (reference: 
normal weight) or being inactive. Among children, obese children had also the highest 
costs. CONCLUSIONS: These results suggest that the burden of obesity in Ontario 
is considerable.
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OBJECTIVES: Treatment with strong opioids is connected with frequent and prob-
lematic side effects where one of the most common is Opioid Induced Constipation 
(OIC). The discomfort of OIC can limit an effective pain therapy. Further, little is 
known about the cost implications of OIC. The objective of this study was to estimate 
the direct and indirect costs for patients with OIC after treatment with strong opioids. 
METHODS: The study is based on patient data from a Swedish non-interventional, 
follow-up study, UPPSIKT (UPPföljning Starka opioider I Klinisk Terapi). The cost 
analysis is based on 197 patients treatmed with strong opioids during a six-month 
period. Direct and indirect costs are calculated per patient month and the cost for 
constipation is estimated as the difference between patient months with and without 
constipation. RESULTS: Around 60–70% of the patients reported to experience some 
degree of problem with constipation each month. The total number of patient months 
with no, mild, moderate and severe constipation were 419, 302, 288 and 135 months 
respectively. The total costs per patient month with severe problems with constipation 
were signiﬁcantly higher than for patients with mild, moderate or no constipation. 
Patients with severe constipation had the highest total costs, 14,639 SEK per patient 
month, while patients with mild, moderate and no problems have 11,481 SEK, 10,443 
SEK and 9,924 respectively. Patients with severe constipation reported on average a 
lower quality of life compared to the other patients in the study. CONCLUSIONS: 
The results from our cost analysis indicate that constipation associated with opioid 
use has the potential to increase the costs to society. The study also concludes that 
patients with severe constipation experience a lower quality of life than patients with 
fewer problems.
PSY20
COSTS AND COST DRIVERS OF IMMUNE TOLERANCE INDUCTION (ITI) 
IN PATIENTS WITH HEMOPHILIA AND INHIBITORS
Bojke C1, Botteman MF2, Wilke CT3, Stephens JM2, Kroner B4
1Pharmerit International, Fishergate, York, UK, 2PharMerit North America LLC, Bethesda, 
MD, USA, 3University of Illinois at Chicago, Chicago, IL, USA, 4RTI International, Rockville, 
MD, USA
OBJECTIVES: Patients with hemophilia and high-titre inhibitors often attempt to 
achieve long-term tolerance to factor VIII (FVIII) via ITI. This analysis presents a 
conceptual economic model of ITI from a US health care perspective. METHODS: A 
simulation model was developed to estimate the total costs of FVIII incurred by deﬁned 
cohorts of patients with hemophilia with various proﬁles undergoing different ITI 
